ExPEC Glycoconjugate Vaccine Formulation Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current glycoconjugate vaccines against ExPEC are not robust enough to withstand multiple environmental stresses such as freeze/thaw, agitation, and thermal stress, leading to stability issues and potential toxicity or altered immunogenicity, necessitating a formulation that ensures chemical, physical, and biological stability across various conditions.
Innovation Solution
The development of new formulations comprising E. coli O antigen polysaccharides covalently bound to a carrier protein, with specific concentrations of sorbitol, methionine, potassium/sodium phosphate buffer, and surfactants like PS80, which enhance stability against freeze/thaw, thermal, and metal-induced oxidation stresses, and are compatible with various container materials.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the existing ExPEC vaccine formulation is used, then it is acceptable for short-term storage at 2-8°C and in-use stability, but it is not robust upon freeze/thaw and under agitation stress
Solution Approach 1:
The patent modifies the formulation parameters by changing the buffer system from Tris to potassium/sodium phosphate, adjusting pH to 6.5-7.5, and incorporating specific stabilizing excipients (sorbitol 3-8%, methionine 5-15 mM, surfactant 0.01-0.2%). These parameter changes enable the formulation to withstand freeze/thaw cycles and agitation stress while maintaining stability at 2-8°C
Solution Approach 2:
The patent introduces specialized excipients as intermediary substances that mediate between the vaccine components and environmental stresses. Specifically, sorbitol and methionine act as stabilizing agents that protect the glycoconjugate from degradation during freeze/thaw and agitation, while the phosphate buffer system mediates pH stability across varying conditions
2Duration of action of stationary object
If the formulation is designed for long-term storage at low temperatures, then stability is improved, but compatibility with different storage containers and materials becomes more challenging
Solution Approach 1:
The patent creates a universal formulation that can be stored in multiple container types (bags, bottles, vials, prefilled syringes) and is compatible with various materials including plastic, glass, and rubber. The modified phosphate buffer system and stabilizing excipients ensure the formulation maintains stability across different storage conditions and container materials, enabling flexible distribution and storage options
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These formulations provide improved stability and longer shelf life for ExPEC vaccines, maintaining biological activity and preventing aggregation under stress conditions, allowing for broader storage and transportation options.
Implementation Method 1
The composition comprises a tonicity modifier, such as sorbitol or sucrose
Implementation Method 2
The composition comprises an anti-oxidant, such as methionine or EDTA
Implementation Method 3
The composition comprises a buffer, such as a potassium/sodium phosphate buffer
Implementation Method 4
The composition comprises a surfactant
Data Source
AI summary
Compositions and methods for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) are described. In particular, multivalent vaccines containing O-antigen polysaccharide covalently bound to an exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein that can withstand multiple environmental stresses are describe.